Funding for this research was provided by:
Ruhr-Universität Bochum
Article History
Received: 3 March 2022
Revised: 12 May 2022
Accepted: 15 May 2022
First Online: 28 May 2022
Declarations
:
: The authors declare no conflict relevant to the content of this manuscript. JA declares no conflict of interest. SF received speaker’s or board honoraria from Biogen, BMS, Celgene, Novartis and Roche and grant support from DMSG, Hertie-Stiftung, Ruhr-University Bochum, Lead Discovery GmbH and Novartis, unrelated to the content of this manuscript. CS reports personal fees / speaker’s honoraria from Teva Pharma GmbH and Desitin GmbH, as well as non-financial support and other support from Registry-Euro-HD-Network, ENROLL-HD study (CHDI), MitoNet, PRIDE-HD (TEVA, Neurosearch), PROOF-HD (Prilenia), LEGATO (TEVA), and Amaryllis (Pfizer), AFQ056 (Novartis), ASO (IONIS Pharmaceuticals, Roche AG, WAVE) for the conducting of studies and grants from Biogen, the German Huntington foundation and CHDI all outside the submitted work and without relevance to the manuscript.
: All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethic Committees of all sides that are part of the global multi-center longitudinal observational study ENROLL-HD. They are required to obtain and maintain local ethical approval (ClinicalTrials.govIdentifier: NCT01574053).